The one therapy available for patients with leprechaunism thus far is recombinant IGF1, aiming to prevent compensatory hyperinsulinemia (23). IGF has with regard to the six% of the glucose-reducing action impact of insulin and has a similar construction to it, consequently it is ready to bind to insulin receptors triggering peripheral glucose uptak